The World Health Organization (WHO) has set ambitious targets for 2030, known as the 90-70-90 targets, to eliminate cervical cancer as a public health threat. These include ensuring that 90% of girls are vaccinated against HPV by the age of 15, 70% of women are screened by age 35 and again by 45, and 90% of women with cervical disease receive treatment. Achieving these goals could significantly reduce the incidence and mortality rates associated with cervical cancer.

Recent studies conducted by PATH in collaboration with immunization program managers have shed light on the operational context and ongoing costs of HPV vaccine delivery. This research focused on a two-dose vaccination schedule across six countries: Ethiopia, Guyana, Rwanda, Senegal, Sri Lanka, and Uganda. Notably, Rwanda has emerged as a leader in this initiative, achieving vaccination coverage rates close to 98%. Such success stories highlight the potential for widespread immunization to transform public health outcomes.

Despite the progress, challenges remain. The tragedy of cervical cancer lies not only in its prevalence but also in the stark inequalities that underpin its impact. Women in low- and middle-income countries account for more than 90% of cervical cancer deaths, underscoring the urgent need for targeted interventions and equitable access to healthcare resources. As one health advocate noted, “Cervical cancer should no longer be killing women,” emphasizing the moral imperative to address this preventable disease.

The HPV vaccine is a critical tool in the fight against cervical cancer, yet its uptake faces hurdles, particularly as vaccination typically occurs during adolescence when routine pediatric visits decline. This gap in healthcare access can hinder vaccination efforts, making it essential for health systems to innovate and adapt to ensure that young girls receive this life-saving vaccine.

Looking ahead, the first World Cervical Cancer Elimination Day was marked in November 2025, signaling a global commitment to this cause. The momentum generated by this initiative could catalyze further investments in cervical cancer prevention and treatment, making it a financing priority for governments and health organizations worldwide. The window for action is open, and the tools are at hand to make significant strides toward eliminating cervical cancer.

As we move forward, the uncertainty surrounding the full implementation of these initiatives remains. Details remain unconfirmed regarding the extent of funding and resources that will be allocated to meet the WHO’s targets. However, the commitment to cervical cancer elimination is clear, and the potential for a future where this disease is no longer a public health threat is within reach.

The post Hpv vaccine: The Critical Role of the in Cervical Cancer Elimination appeared first on DG News Sport.

The emergence of the BA.3.2 variant, colloquially referred to as the cicada COVID variant, has significant implications for public health in the United States and beyond. Detected in at least 25 states as of February 11, 2026, this highly mutated strain of SARS-CoV-2 is raising alarms due to its potential ability to evade immunity provided by vaccines and previous infections. With 70 to 75 mutations in its spike protein, BA.3.2 is notably different from its predecessors, prompting health officials to monitor its spread closely.

First identified in South Africa in November 2024, BA.3.2 has since been reported in at least 23 countries. Its classification as a ‘variant under monitoring’ by the World Health Organization (WHO) in December 2025 underscores the variant’s potential to complicate the ongoing battle against COVID-19. The variant was first detected in the U.S. in June 2025, and its prevalence has been increasing, with 11% of wastewater samples indicating the presence of BA.3.2 during the week ending March 21, 2026.

Common symptoms associated with BA.3.2 include cough, fever or chills, sore throat, congestion, shortness of breath, loss of smell or taste, fatigue, headache, and gastrointestinal issues such as diarrhea or vomiting. These symptoms are similar to those of other COVID-19 variants, making it challenging for individuals to distinguish between them without testing.

Experts are cautiously optimistic about the existing vaccines’ effectiveness against BA.3.2. Dr. Amesh A. Adalja noted that while the variant may evade some immune responses, the current vaccines are likely to protect against severe illness, which remains the primary concern. However, the exact impact of BA.3.2 on disease severity is still unclear, with Dr. Adolfo García-Sastre stating that there is no evidence to suggest that it is causing more severe disease or hospitalizations in regions where it is prevalent.

Andrew Pekosz, Ph.D., emphasized the variant’s numerous mutations, which may allow it to present differently to the immune system, complicating the body’s ability to recognize and combat the virus effectively. This characteristic raises questions about the long-term efficacy of vaccines and the potential need for updated formulations to address emerging variants.

While the situation surrounding BA.3.2 continues to evolve, uncertainties remain. The reasons for the variant’s resurgence are not fully understood, and health officials are monitoring its spread and impact closely. Details remain unconfirmed regarding how effective current vaccines will be against this variant, leaving public health experts and the general population on alert.

As the cicada COVID variant spreads, continued vigilance and research will be essential in navigating the challenges it presents. The response from health authorities and the scientific community will play a critical role in determining how effectively society can mitigate the impact of BA.3.2 and protect public health moving forward.

The post Cicada COVID Variant: Understanding the BA.3.2 Threat appeared first on DG News Sport.